Literature DB >> 9748024

Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

O Kantarci1, A Siva, M Eraksoy, R Karabudak, N Sütlaş, J Ağaoğlu, F Turan, M Ozmenoğlu, E Toğrul, M Demirkiran.   

Abstract

OBJECTIVE: To examine the natural history, survival, and prognostic factors in a sample of Turkish MS patients.
METHOD: This multicenter study included 1,259 definite MS patients diagnosed according to the criteria of Poser et al. Actuarial analysis of selected disability levels of 3, 6, 8, and 10 achieved with the Expanded Disability Status Scale (EDSS); a multivariate Cox regression analysis for prognostic factors related to time to reach EDSS > or = 6; and Pearson's correlation coefficient for individual factors were performed.
RESULTS: The survival (+/- SE) at 15 years from onset was 94.6 +/- 2.9%, and at 25 years was 89.0 +/- 5.8%. The disability reached by 15 years was EDSS > or = 3 in 66.4%, EDSS > or = 6 in 41.2%, EDSS > or = 8 in 10.5%, and EDSS = 10 in 5.4%. The most significant unfavorable prognostic factors were progressive course (relative risk [RR], 3.73; CI, 2.71 to 5.13) and sphincter symptoms at onset (RR, 1.86; CI, 1.23 to 2.82), followed by male sex, motor symptoms at onset, and a high attack frequency within the first 5 years. Primary progressive disease was correlated positively with male sex (r = 0.0895, p = 0.001), older age (r = 0.1807, p = 0.000), and motor (r = 0.1433, p = 0.000) or sphincter symptoms (r = 0.1001, p = 0.000) at onset, unlike relapsing-remitting and secondary progressive disease.
CONCLUSIONS: Although a slightly better prognosis is observed in the Turkish MS population, early prognostic factors are similar to most of the previous Western series. Primary progressive disease, mostly seen in older men with motor and sphincter involvement at onset, has a worse prognosis and may represent a distinct behavioral variant of MS.

Entities:  

Mesh:

Year:  1998        PMID: 9748024     DOI: 10.1212/wnl.51.3.765

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

1.  Relapses and disability accumulation in progressive multiple sclerosis.

Authors:  M Mateo Paz Soldán; Martina Novotna; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2014-11-14       Impact factor: 9.910

2.  Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Authors:  Valentina Tomassini; Andrea Paolillo; Pierluigi Russo; Elisabetta Giugni; Luca Prosperini; Claudio Gasperini; Guido Antonelli; Stefano Bastianello; Carlo Pozzilli
Journal:  J Neurol       Date:  2005-09-14       Impact factor: 4.849

3.  Depression in multiple sclerosis: a longitudinal analysis.

Authors:  Claudia C Beal; Alexa K Stuifbergen; Adama Brown
Journal:  Arch Psychiatr Nurs       Date:  2007-08       Impact factor: 2.218

4.  Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis.

Authors:  Muhammad Taimur Malik; Brian C Healy; Leslie A Benson; Pia Kivisakk; Alexander Musallam; Howard L Weiner; Tanuja Chitnis
Journal:  Neurology       Date:  2014-05-21       Impact factor: 9.910

Review 5.  Multiple sclerosis in the elderly patient.

Authors:  Amer Awad; Olaf Stüve
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

6.  Impact of multiple sclerosis relapses on progression diminishes with time.

Authors:  H Tremlett; M Yousefi; V Devonshire; P Rieckmann; Y Zhao
Journal:  Neurology       Date:  2009-11-04       Impact factor: 9.910

7.  Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications.

Authors:  Shien Guo; Duygu Bozkaya; Alexandra Ward; Judith A O'Brien; Khajak Ishak; Randy Bennett; Ahmad Al-Sabbagh; Dennis M Meletiche
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

8.  Prevalence of Multiple Sclerosis in the Middle Black Sea Region of Turkey and Demographic Characteristics of Patients.

Authors:  Neslihan Akdemir; Murat Terzi; Nilden Arslan; Musa Onar
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

9.  Contribution of relapses to disability in multiple sclerosis.

Authors:  Claire Hirst; Gillian Ingram; Owen Pearson; Trevor Pickersgill; Neil Scolding; Neil Robertson
Journal:  J Neurol       Date:  2008-01-23       Impact factor: 4.849

10.  Evidence for a two-stage disability progression in multiple sclerosis.

Authors:  Emmanuelle Leray; Jacqueline Yaouanq; Emmanuelle Le Page; Marc Coustans; David Laplaud; Joël Oger; Gilles Edan
Journal:  Brain       Date:  2010-04-27       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.